CDK12 and neoplasm: One group established 42 ovarian cancer PDX models with different sensitivity to cisplatin, revealing that cyclin dependent kinase 12 (CDK12) mRNA expression was negatively related to cisplatin sensitivity and positively associated with tumor recurrence rate in high-grade serous/endometrioid ovarian cancer PDX samples in vivo, suggesting that the CDK12 may be an important gene in ovarian cancer cell resistance to cisplatin 57.